
Robert Hariri, SmarterTogether via Youtube
FDA OKs a trial for a new Covid-19 therapy after an unusual publicity campaign touts its potential — with help from Rudy Giuliani
After taking to the Wall Street Journal to tout the potential of taking their lead natural killer cell therapy and leapfrogging from cancer to Covid-19, while gaining an influential advocate in the White House, Celularity CEO Robert Hariri now has the IND he was looking for from the FDA to start testing this approach in patients.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.